I finally got caught up on WH Task Force briefings from the last 1.5 weeks.
Videos are on the WH youtube channel, transcripts are here:
Here are my highlights from Wednesday:
While still high, new daily cases continue to decline and are now below last summer’s peak. New hospitalizations and deaths also declining.
14.5M doses were allocated to the states this week, with an additional 2.1M doses allocated directly to pharmacies. [Side note: DH says he has several co-workers that have successfully gotten appointments through CVS and their site is a lot more user friendly than most of the government ones, if anyone knows someone eligible and still trying to schedule.]
7 day average of vaccinations administered is 1.4M/day, down from 1.7M/day the week before due to weather. Shipping delays due to weather are now caught up, so hopefully vaccination sites will catch up as well.
Federal government is providing vaccinators and support staff to try to expedite administration.
If the J&J vaccine has its EUA approved 3-4M doses could be allocated next week (same formula as current allocations) and 20M doses by end of March. 100M doses by end of June, back end loaded, but they are trying to provide support to expedite.
Variants:
B.1.1.7 (UK) ~1900 cases in 45 states
B.1.351 (SAfrica) 46 cases in 14 states
P.1 (Brazil) 5 cases in 4 states
Working on increasing surveillance
NIH has launched a new initiative to study long term symptoms, designated PASC (post-acute sequelae of SARS-CoV-2 infection). These range from mildly annoying to incapacitating and can occur even in those not hospitalized during the acute phase. Fauci referenced this study:
One of the key goals of the NIH initiative is to better understand the biological cause (pathogenesis) of the ongoing symptoms to improve treatment guidance.
Additional 2/22 highlights:
Regarding updating treatment guidance for the variants. “We already know particularly that the South African variant is, in fact, obviating the effect of several of the monoclonal antibodies that people have developed.”
They are working on behavioral guidance for individuals that have been vaccinated. (I think @Beth33 had asked about this.) Community level guidance will still need to be followed (masks, distancing), but there may be places it is appropriate to alter personal behaviors. (They highlighted that there is one instance already in CDC quarantine guidelines: “People who have been in close contact with someone who has COVID-19 are not required to quarantine if they have been fully vaccinated against the disease within the last three months and show no symptoms.”) More likely to come after post-vaccination transmission is better understood. Timeframe expected to lengthen as trial data continues to come in.
Additional 2/19 highlights:
Additional FEMA mega vaccination sites coming:
PA-Philadelphia-6k/day
FL-4 in Orlando, Miami, Jacksonville, and Tampa-total 12k/day
[side note: Houston FEMA mega site went fully online today and administered 5.6k vaccines. Dallas and Arlington sites also online this week.]
Vaccine safety monitoring highlights
Approx half of people don’t feel well after second dose. Plan to take it easy. [Side note: Don’t get same day as your spouse if you can help it so you aren’t both down at same time.]
4.5 cases of anaphylaxis per million doses (roughly in same range as other vaccines)
There have been 113 reports of death after COVID-19 vaccinations not believed linked to the vaccinations, and those are statistically consistent with the all-cause mortality rates for the relevant populations (2/3 were in LTC facilities).
Went into details of lower age trial timelines, but the gist of it is that 12-16 year olds will hopefully have a vaccine available in the fall, and then 5-11 years old in Q1 2022.
Revisited the one dose vs two dose approach yet again. They are concerned about the durability of only giving one dose of a two dose regimen, especially given that optimal protection may be needed due to variants. Also concerned that a sub-optimal dosing regimen could lead to a greater number of variants. (Immune response to second dose is 10x the response to the first dose.)
Additional 2/17 highlights:
Lots of talk about “breakthrough infection transmission” for those already vaccinated and the viral load studies coming in (which should correlate) if anyone wants to read details. More studies underway.